Other
Finnish Breast Cancer Group
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
Failure Rate
0.0%
0 terminated/withdrawn out of 3 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
100%
3 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 3
3(100.0%)
3Total
Phase 3(3)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT00639210Phase 3Completed
BREAST CANCER AND EXERCISE
Role: lead
NCT00593697Phase 3Completed
The Synergism Or Long Duration (SOLD) Study
Role: lead
NCT00114816Phase 3Completed
Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer
Role: lead
All 3 trials loaded